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Anaplastic lymphoma kinase rearranged (ALK+) non–small-cell lung cancer has shown remarkable sensitivity 
to crizotinib.1 The utility of rechallenge with crizotinib after 
progression and time on other therapies has not previously 
been described.
A 63-year-old, white, female never-smoker had a stage 
IIIA adenocarcinoma resected by pneumonectomy after neo-
adjuvant carboplatin and paclitaxel. Eight months later, she 
experienced widespread recurrence at various sites including 
right adrenal, right kidney, and abdominal lymph nodes.
Molecular analysis revealed ALK positivity by 
fluorescence in situ hybridization.1 In August 2009, she 
commenced crizotinib (250 mg twice daily).1 After 2 months, 
her right renal lesion decreased in size by 50% per Response 
Evaluation Criteria in Solid Tumors, and all sites of disease 
showed decreased metabolic activity. In April 2010, she had 
isolated progression in the right adrenal and received 30 Gy 
to this site using stereotactic body radiotherapy with con-
tinuation of the crizotinib. In August 2010, she progressed in 
a left retroperitoneal lymph node and received additional 
stereotactic body radiotherapy. Positron emission tomography 
and computed tomography (PET/CT) in January 2011 showed 
improvement in the areas treated with radiotherapy but 
additional progression in retroperitoneal and mediastinal 
lymph nodes. Crizotinib was discontinued in February 2011.
From February 2011 through June 2012 she received 
pemetrexed (500 mg/m2 every 21 days) and achieved com-
plete radiographic response on PET/CT by August 2011. In 
May 2011, she received stereotactic radiosurgery on two new 
brain metastases. In June 2012, she developed progression in 
a right renal lesion, not amenable to radiotherapy, and peme-
trexed was discontinued. In July 2012, crizotinib was reiniti-
ated, 250 mg twice daily. After 6 weeks of therapy, a PET/CT 
showed a decrease in the size of her renal lesion by 44%, and 
resolution of all hypermetabolic activity (Fig. 1).
DISCUSSION
Our patient experienced an initial progression-free 
survival for 8 months, but a total of nearly 18 months of dis-
ease control because of crizotinib, using radiotherapy to treat 
oligoprogressive resistant clones.2 Our patient then had a pro-
longed radiographic response to second-line pemetrexed.3,4 
Her dramatic response on rechallenge with crizotinib after 
16 months of intervening pemetrexed is reminiscent of the 
benefit when EGFR mutant patients are rechallenged with 
an epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor (TKI), after a period of time either on non-EGFR–
directed therapies or off all therapy.5 These data suggest that, 
although TKI-sensitive clones of oncogene-addicted cancers 
may be dramatically suppressed, they still survive treatment 
with the relevant TKI. These TKI-sensitive survivors may 
then re-emerge along Darwinian evolutionary lines under 
selection pressures that are not directly related to the path-
way affected by the TKI. In the acquired resistance setting, 
continuing the TKI during next-line chemotherapy could be 
one way of addressing this phenomenon. However, whether 
a combination approach would be better or worse than seq-
uentially alternating selection pressures is currently unclear. 
In the crizotinib-acquired resistance setting, rechallenge 
of ALK+ patients with crizotinib after chemotherapy 
versus continuation of both chemotherapy and crizotinib 
together (if tolerable), should be considered for further 
investigation.
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FIGURE 1. A, Right renal lesion, which developed on pemetrexed after prior crizotinib, and (B), subsequent response  
after 6 weeks of crizotinib rechallenge.
